ESO-Shanghai 20: phase III clinical trial of anti-PD-1 therapy with local intervention for oligometastatic ESCC

作者：Guangmin Mao, Zhuocheng Xin, Qingsong Fan, Huijuan Zhu, Jinjun Ye, Long Zhou, Yufeng He, Benhua Xu, Cheng Chen, Zhijun Li, X. Gu, Xianfeng Li, Xiaomin Wang, Junjun Guo, Zhengyang Xu, Peng Wan, Yunxia Zhang, Fuzheng Zhang, Canhong Huang, Qiong Yi, Jiang-Qiong Huang, Shi‐Xiong Liang, Junqiang Chen, Lin Yu, Qingliang Fang, Yun Chen, Dashan Ai, Hongcheng Zhu, Shengnan Hao, Qi Liu, Kuaile Zhao · 发表于：Future Oncology · 年份：2025 · DOI：10.1080/14796694.2025.2534770 · 被引用次数：3 · 研究领域：Cancer Immunotherapy and Biomarkers、Hepatocellular Carcinoma Treatment and Prognosis、Lung Cancer Diagnosis and Treatment

Anti-PD-1 therapy combined with or without chemotherapy is the standard regimen for metastatic esophageal cancer. Oligometastatic carcinoma is an intermediate state of tumor development between locally advanced and widespread metastasis, with potential long-term survival. The ESO-Shanghai 13 trial demonstrated that systemic therapy combined with local intervention improved progression-free survival and overall survival in patients with oligometastatic esophageal squamous cell carcinoma. However, it is a phase II trial and has two systemic treatment regimens including chemotherapy and chemoimmunotherapy. There were only 43 patients treated with checkpoint inhibition therapy with or without local intervention therapy in ESO-Shanghai 13. To further assess the efficacy of Anti-PD-1 therapy with local intervention therapy in oligometastatic esophageal patients, we initiated a multicenter randomized controlled phase III clinical trial, ESO-Shanghai 20.Clinical trial registration NCT06190782 (ClinicalTrials.gov).